Jackson Grant Investment Advisers’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $7.64M | Sell |
30,346
-294
| -1% | -$63.3K | 2.37% | 6 |
|
|
2026
Q1 | $6.66M | Sell |
30,640
-557
| -2% | -$124K | 2.22% | 8 |
|
|
2025
Q4 | $7.13M | Sell |
31,197
-247
| -0.8% | -$56.3K | 2.35% | 8 |
|
|
2025
Q3 | $7.28M | Buy |
31,444
+137
| +0.4% | +$27.9K | 2.43% | 8 |
|
|
2025
Q2 | $5.81M | Buy |
31,307
+147
| +0.5% | +$27.3K | 2.13% | 8 |
|
|
2025
Q1 | $6.53M | Buy |
31,160
+26
| +0.1% | +$5.05K | 2.53% | 7 |
|
|
2024
Q4 | $5.53M | Buy |
31,134
+285
| +0.9% | +$52.4K | 2.13% | 8 |
|
|
2024
Q3 | $6.09M | Buy |
30,849
+150
| +0.5% | +$28K | 2.28% | 8 |
|
|
2024
Q2 | $5.27M | Sell |
30,699
-215
| -0.7% | -$35.6K | 2.13% | 8 |
|
|
2024
Q1 | $5.63M | Sell |
30,914
-83
| -0.3% | -$14.3K | 2.31% | 8 |
|
|
2023
Q4 | $4.8M | Buy |
30,997
+185
| +0.6% | +$27K | 2.13% | 8 |
|
|
2023
Q3 | $4.59M | Buy |
30,812
+165
| +0.5% | +$24.2K | 2.21% | 9 |
|
|
2023
Q2 | $4.13M | Buy |
30,647
+172
| +0.6% | +$25.2K | 1.92% | 11 |
|
|
2023
Q1 | $4.86M | Buy |
30,475
+244
| +0.8% | +$37.3K | 2.28% | 10 |
|
|
2022
Q4 | $4.89M | Buy |
30,231
+145
| +0.5% | +$22.2K | 2.36% | 8 |
|
|
2022
Q3 | $4.04M | Buy |
30,086
+167
| +0.6% | +$24K | 2.11% | 12 |
|
|
2022
Q2 | $4.58M | Buy |
29,919
+161
| +0.5% | +$24.6K | 2.27% | 11 |
|
|
2022
Q1 | $4.82M | Buy |
29,758
+171
| +0.6% | +$24.8K | 2.03% | 12 |
|
|
2021
Q4 | $4.01M | Buy |
29,587
+115
| +0.4% | +$13.6K | 2.04% | 13 |
|
|
2021
Q3 | $3.18M | Sell |
29,472
-776
| -3% | -$88.7K | 1.42% | 15 |
|
|
2021
Q2 | $3.41M | Sell |
30,248
-268
| -0.9% | -$30.2K | 1.5% | 15 |
|
|
2021
Q1 | $3.3M | Buy |
30,516
+225
| +0.7% | +$24.1K | 1.52% | 15 |
|
|
2020
Q4 | $3.25M | Buy |
30,291
+183
| +0.6% | +$17.6K | 1.66% | 15 |
|
|
2020
Q3 | $2.64M | Sell |
30,108
-291
| -1% | -$27.4K | 1.59% | 15 |
|
|
2020
Q2 | $2.98M | Sell |
30,399
-892
| -3% | -$78.5K | 1.9% | 13 |
|
|
2020
Q1 | $2.38M | Sell |
31,291
-316
| -1% | -$26.9K | 1.76% | 14 |
|
|
2019
Q4 | $2.8M | Sell |
31,607
-1,004
| -3% | -$83.3K | 1.51% | 16 |
|
|
2019
Q3 | $2.47M | Sell |
32,611
-1,639
| -5% | -$112K | 1.4% | 16 |
|
|
2019
Q2 | $2.49M | Sell |
34,250
-1,323
| -4% | -$104K | 1.45% | 16 |
|
|
2019
Q1 | $2.87M | Buy |
35,573
+81
| +0.2% | +$6.63K | 1.72% | 15 |
|
|
2018
Q4 | $3.27M | Sell |
35,492
-113
| -0.3% | -$9.94K | 2.3% | 9 |
|
|
2018
Q3 | $3.37M | Buy |
35,605
+434
| +1% | +$41.2K | 2.11% | 9 |
|
|
2018
Q2 | $3.26M | Sell |
35,171
-1,200
| -3% | -$117K | 2.24% | 9 |
|
|
2018
Q1 | $3.44M | Sell |
36,371
-75
| -0.2% | -$8.24K | 2.41% | 9 |
|
|
2017
Q4 | $3.52M | Sell |
36,446
-504
| -1% | -$47.5K | 2.38% | 8 |
|
|
2017
Q3 | $3.28M | Buy |
36,950
+4,215
| +13% | +$321K | 2.37% | 8 |
|
|
2017
Q2 | $2.37M | Buy |
32,735
+678
| +2% | +$45.6K | 1.84% | 12 |
|
|
2017
Q1 | $2.09M | Buy |
32,057
+57
| +0.2% | +$3.58K | 1.68% | 13 |
|
|
2016
Q4 | $2M | Buy |
32,000
+243
| +0.8% | +$14.8K | 1.7% | 13 |
|
|
2016
Q3 | $2M | Buy |
+31,757
| New | +$2.06M | 1.66% | 13 |
|
|
2016
Q2 | – | Sell |
-29,651
| Closed | -$1.69M | – | 163 |
|
|
2016
Q1 | $1.69M | Sell |
29,651
-920
| -3% | -$51.3K | 1.55% | 13 |
|
|
2015
Q4 | $1.81M | Buy |
+30,571
| New | +$1.76M | 1.72% | 12 |
|
Other funds holding ABBV
ECSS
ATO
Jackson Grant Investment Advisers's ABBV Position: Q2 2026 in Review
Jackson Grant Investment Advisers reduced its AbbVie (ABBV) stake by 0.96% in Q2 2026, selling an estimated $63.3K and leaving 30,346 shares worth $7.64M. The position accounts for 2.37% of the portfolio, ranked #6.
Jackson Grant Investment Advisers first reported a position in ABBV in Q4 2015 and has held it in 42 quarters since. 2,089 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Jackson Grant Investment Advisers held 30,346 shares of AbbVie worth $7.64M as of Q2 2026.
- Jackson Grant Investment Advisers sold 294 AbbVie shares in Q2 2026, an estimated $63.3K.
- AbbVie made up 2.37% of Jackson Grant Investment Advisers's portfolio in Q2 2026, its #6 holding.
- Jackson Grant Investment Advisers first reported a position in AbbVie in Q4 2015 and has held it in 42 quarters since.
- 2,089 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Jackson Grant Investment Advisers's 13F filing for Q2 2026, filed 31 Jul 2026.